KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, T. JANÁSKOVÁ, J. ROUBEC, P. POPELKOVÁ, T. BÁRTEK, D. SIXTOVÁ, E. PAVLÍKOVÁ, T. VLÁSEK, F. CHALOUPKA a Jana SKŘIČKOVÁ. Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival. In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. doi:10.1016/j.lungcan.2012.05.064.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival
Autoři KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, T. JANÁSKOVÁ, J. ROUBEC, P. POPELKOVÁ, T. BÁRTEK, D. SIXTOVÁ, E. PAVLÍKOVÁ, T. VLÁSEK, F. CHALOUPKA a Jana SKŘIČKOVÁ.
Vydání 13th Central European Lung Cancer Conference, 2012.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 30200 3.2 Clinical medicine
Stát vydavatele Irsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 3.392
Organizační jednotka Lékařská fakulta
ISSN 0169-5002
Doi http://dx.doi.org/10.1016/j.lungcan.2012.05.064
UT WoS 000305842300065
Klíčová slova anglicky lung cancer; erlotinib
Změnil Změnil: Mgr. Michal Petr, učo 65024. Změněno: 17. 8. 2012 14:14.
Anotace
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients. The tolerance of adjutant chemotherapy and implementation of planned dose intensity remains a substantial problem, which most likely reflects the difficulty associated with CDDP-based chemotherapy. NCIC CTG BR.10, IALT and ANITA trials reported treatment-related deaths, accounting for 0.8–1.7%. In ANITA trial, median of planned dose was 56.3% in NVB and 76.1% in CDDP. Only 50% of patients finished all of 4 cycles planned. New studies targeting more tolerable regimens are needed. CDDP-based treatment is preferred, but several studies showed similar effectiveness and better tolerance of the combination of carboplatin (AUC5) and paclitaxel, pemetrexed or vinorelbine. Only few data exist about vinorelbine given orally in adjuvant chemotherapy (ACT).
VytisknoutZobrazeno: 24. 10. 2021 18:47